Despite the performance, the company expects to be at the lower end of its revenue guidance window for the year of between €2 ...

Despite the potential in oncology, BNTX's current valuation is high relative to its non-COVID revenue prospects, warranting a ...

On Monday, BioNTech SE (NASDAQ:BNTX) reported third-quarter revenues of 1.244 billion euros (or $1.36 billion), up from 895.3 ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...

Children aged 6 months and older may need one to three doses of either vaccine, depending on their age and vaccination status ...

British prosecutors accuse Thomas Kwan of posing as a nurse and injecting 72-year-old Patrick O'Hara with a dangerous ...

John Newman, an analyst from Canaccord Genuity, maintained the Buy rating on BioNTech SE (BNTX – Research Report). The associated price ...

Driven by the early approval of its updated COVID-19 vaccine, BioNTech far exceeded analysts’ expectations in the third ...

Dr. Christopher Sanford, an expert in travel and tropical medicine at the University of Washington, previously told USA TODAY ...

The FDA has lifted its clinical hold on Novavax's combined COVID-19 and influenza vaccine trial, finding no link between the ...

The COVID-19 vaccine maker reported a third-quarter net profit of 198.1 million euros, up from 160.6 million euros a year ago. BioNTech reported EPS of 81 cents, up from 66 a year ago.